Dynamics of the structure of non-insulin antihyperglycemic drug use in the treatment of type 2 diabetes mellitus (data from the Moscow segment Federal Diabetes Registry)

N.A. Demidov

Shcherbinskaya Outpatient Clinic, Moscow, Russia

Background: Type 2 diabetes mellitus (DM2) remains one of the leading causes of cardiovascular complications, which emphasizes the need for the use of antihyperglycemic drugs that can not only control glucose levels, but also reduce the risk of cardiovascular diseases (CVD) and chronic kidney disease (CKD).
Objective: Assessment of the dynamics of the use of non-insulin antihyperglycemic drugs and dapagliflozin based on data from the Moscow segment of the Federal Diabetes Registry for the period from 2016 to 2025.
Materials and methods: The study was a retrospective analysis of anonymized data. The data source for assessing the frequency of use of various antihyperglycemic drugs included samples of patients from the Moscow segment of the FDR who received therapy with various antihyperglycemic drugs in 2016, 2020, and 2025. To assess the main characteristics of patients with DM2 receiving dapagliflozin therapy, a sample of patients from the Moscow segment of the FDR was formed as of 03/08/2025.
Results: During the follow-up period from 2016 to 2025, the number of patients with DM2, according to the Moscow segment of the FDR, increased by 15.4% (from 303.1 to 349.7 thousand people). The proportion of patients with DM2 using DPP-4 inhibitors has increased by 7.3 times over 10 years (from 3.4 to 24.7%), the proportion of SGLT-2 inhibitors by 24.4 times (from 0.8% to 19.5%), and the proportion of GLP-1 arginine by 39 times (from 0.1 to 3.9%)
Conclusion:
1. The frequency of using drugs with proven cardio-nephroprotective properties in the treatment of patients with type 2 diabetes mellitus has been steadily increasing over the past 10 years.
2. Over the past 10 years, SGLT-2 inhibitors remain the leading class of antihyperglycemic drugs with proven cardio-nephroprotective properties.
3. Dapagliflozin is the most frequently used drug from the SGLT-2 inhibitor class when used in patients with type 2 diabetes.

Keywords

About the Authors

Nikolay A. Demidov, Cand. Sci. (Med.), Endocrinologist, Shcherbinskaya Outpatient Clinic, Moscow, Russia; Nicolay13@mail.ru, ORCID:
https://orcid.org/0000-0001-8289-0032, eLibrary SPIN: 7715-4508

Similar Articles